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Elevated plasma levels of C-reactive protein (CRP), an inflammation-sensitive marker, have emerged as an important
predictor of future cardiovascular disease and metabolic abnormalities in apparently healthy men and women.
Here, we performed a systematic survey of common nucleotide variation across the genomic region encompassing
the CRP gene locus. Of the common single-nucleotide polymorphisms (SNPs) identified, several in the CRP promoter
region are strongly associated with CRP levels in a large cohort study of cardiovascular risk in European American
and African American young adults. We also demonstrate the functional importance of these SNPs in vitro.
Introduction
C-reactive protein (CRP) was initially defined as a pro-
tein in serum that binds to the C polysaccharide of Strep-
tococcus pneumoniae (Tillet and Francis 1930) and is the
prototypical protein up-regulated as part of the acute
phase response in humans (Abernathy and Avery 1941).
More recently, elevated CRP has been identified as a bio-
marker for cardiovascular disease (CVD) risk, supple-
mentary to traditional risk factors such as BMI, smok-
ing, diabetes, and cholesterol levels (Ridker et al. 1997,
2000, 2005; Danesh et al. 2000, 2004; Hackam and
Anand 2003). Family and twin studies suggest that ad-
ditive genetic factors account for as much as 40% of the
variance in plasma CRP levels (Pankow et al. 2001; Ret-
terstol et al. 2003; MacGregor et al. 2004), but the spe-
cific genetic determinants remain poorly characterized.
Human genetic association studies of CRP include
several that have assessed the relationship between ge-
notype and plasma CRP levels (Szalai et al. 2002; Zee
and Ridker 2002; Brull et al. 2003; Russell et al. 2004)
or disease risk (Zee and Ridker 2002; Wolford et al.
2003; Russell et al. 2004). These generally have suffered
from lack of functional data on DNA-sequence varia-
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tion. Polymorphisms reported elsewhere as being asso-
ciated with CRP levels include a polymorphism in the
promoter region (Kovacs et al. 2005), a synonymous
polymorphism in exon 2 (Russell et al. 2004; Suk et al.
2005), a polymorphism in the 3′ UTR (Brull et al. 2003),
and a second polymorphism in the 3′ UTR (Russell et
al. 2004). These studies have been restricted to a small
number of polymorphisms within the CRP gene locus,
without consideration of the patterns of variation across
the locus as a whole. Thus, although the reported asso-
ciations suggest that variation at the CRP locus is sig-
nificantly correlated with basal CRP levels, it remains
possible that the observed associations were attributable
to other polymorphisms in strong linkage disequilib-
rium (LD) with the reported polymorphisms, because
none of the prior work demonstrated functional differ-
ences between alleles. Prior analyses have also been
largely restricted to European populations, with no
prior study including 1100 African Americans (AAs).
To explore whether common genetic variants at the
human CRP gene locus influence plasma CRP, we used
an approach that starts with genomic resequencing to
identify all common patterns of nucleotide diversity and
to define common haplotypes in the European American
(EA) and AA populations. We then genotyped a set of
polymorphisms representative of the patterns of com-
mon variation identified in a much larger population-
based study sample, and we identified associations with
specific haplotypes. Lastly, we experimentally validated
the observed associations with polymorphisms in the
promoter region, using in vitro CRP promoter analysis
in a human hepatocyte cell line.
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Table 1
TaqMan Primer and Probe Sequences
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
Table 2
CARDIA Participant Characteristics at Year 15,
by Race and Sex
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
Material and Methods
SNP Discovery, tagSNP Selection, and Genotyping
Polymorphic sites were identified by resequencing of
PCR products tiled across the CRP gene region by use
of standard BigDye Terminator v3.1 chemistry from Ap-
plied Biosystems (ABI). The gene and flanking region
were resequenced in 47 samples: 24 unrelated AAs from
the Coriell AA100 panel and 23 unrelated EAs from the
CEPH pedigrees. Coriell sample identifiers are available
at the Web site of the SeattleSNPs Program for Genomic
Applications. We resequenced 6,800 bp in each sample,
covering the two exons, the intervening intron, and 1.7
kbp 5′ and 2.8 kbp 3′ of the gene. SNP numbering is
based on the GenBank accession number AF449713.
Bins of common SNPs (minor-allele frequency [MAF]
110%) in strong LD, as defined by , were iden-2r 1 0.64
tified within each population by use of LDselect v1.0
(Carlson et al. 2004). Seven tagSNPs were selected for
coverage of all bins in the two sequenced populations.
Relative to AF449713, the seven tagSNPs positions
were 790 (dbSNP rs3093058), 1440 (rs3091244), 1919
(rs1417938), 2667 (rs1800947), 3006 (rs3093066), 3872
(rs1205), and 5237 (rs2808630).
The previous literature has generally used a nomencla-
ture for polymorphism positions relative to the ATG co-
don. Thus, the previously reported promoter polymor-
phism has been referred to as286 (Kovacs et al. 2005),
the synonymous polymorphism in exon 2 has been re-
ferred to as1059 (Russell et al. 2004; Suk et al. 2005),
and the polymorphisms in the 3′ UTR have been referred
to as 1444 (Brull et al. 2003) and 2147 (Russell et
al. 2004). Because our resequencing efforts identified sev-
eral insertion/deletion polymorphisms in the CRP gene
region, numbering relative to an origin such as the ATG
codon would be ambiguous, so we have chosen to refer
to each polymorphism relative to its position in GenBank
accession number AF449713, which details the results
of our polymorphism-discovery survey. For convenience,
here is a brief list of pseudonyms for polymorphisms
reported elsewhere: 717 is 1009 (rs2794521), 286 is
1440 (rs3091244), 1059 is 2667 (rs1800847),1444
is 3014 (rs1130864), and 2147 is 3872 (rs1205).
tagSNPs were genotyped using TaqMan Assays By
Design (ABI) under standard conditions, with the ex-
ception of the triallelic tagSNP (detailed below). Probe
and primer sequences for each assay are listed in table
1. End-point fluorescence values were genotyped man-
ually within the SDS software (ABI) for tagSNPs 790,
3872, and 5237. Threshold cycle (Ct) values from real-
time reads were exported to Excel (Microsoft) and were
used to cluster and manually score genotypes for 1919,
2667, and 3006. The triallelic SNP (1440) was genotyped
in a single tube assay, by use of reagents, at the following
final concentrations in a 5-ml reaction: three TaqMan
probes at 0.2 mM each, two PCR primers at 1 mM each,
1# Universal Mastermix (ABI), 1 M betaine (Sigma-
Aldrich), and 1 ng/ml genomic DNA. Thermal cycling
reactions were performed as follows: 50 for 2 min, 95
for 10 min, and then 45 cycles at 95 for 15 s, 53 for
30 s, and 60 for 1 min. Real-time data were acquired
on the ABI 7900HT instrument. Ct values from real-
time data for all three probes were exported from the
SDS 2.1 software (ABI) and were used to visualize and
manually call genotypes in Excel. Haplotypes for clad-
istic analysis were inferred using PHASE v2.0 (Stephens
and Donnelly 2003).
CARDIA Population Study Sample
The Coronary Artery Risk Development in Young
Adults (CARDIA) study is a population-based study, in-
itiated in 1985, to investigate the evolution of cardio-
vascular risk factors in a large, biracial cohort of young
adults (Hughes et al. 1987; Friedman et al. 1988). Par-
ticipants aged 18–30 years were recruited from four geo-
graphic locations by community-based sampling (Bir-
mingham, AL; Chicago; and Minneapolis) and through
the membership of a large prepaid health plan (Oak-
land). In 1985–1986, baseline examinations of 5,115
participants, or 51% of the eligible persons contacted,
were performed. Participants were contacted every 6 mo
and were re-examined at five follow-up examinations
(year 2 in 1987–1988, year 5 in 1990–1991, year 7 in
1992–1993, year 10 in 1995–1996, and year 15 in 2000–
2001).
The initial study population was approximately bal-
anced with respect to age (45% were aged 18–24 years;
55% were aged 25–30 years), sex (46% men; 54% wo-
men), race (52% AA; 48% EA), and education (40%
had completed 12 years of education; 60% had com-
pleted 112 years). Overall retention rates for follow-up
examinations among surviving participants were 91%
at year 2, 86% at year 5, 81% at year 7, 79% at year
10, and 74% at year 15. The CARDIA database includes
repeated measures of lifestyle, physiologic, and metabolic
risk factors, including smoking, obesity, and physical
66 Am. J. Hum. Genet. 77:64–77, 2005
Figure 1 A GeneSNPs image of CRP, showing the region scanned for polymorphism. Coding regions of exons are shown in blue, and
the UTR is shown in green. Polymorphic positions are indicated with ticks below the axis, and the length of the tick represents MAF in the
combined population. A highly repetitive region of the intron (shown in pink) could not be screened for polymorphism by resequencing. Nonsyn
p nonsynonymous; Synon p synonymous; CDS - coding sequence.
Figure 2 Visual genotype diagram of patterns of common var-
iation at the CRP locus. Each row corresponds to an individual DNA
sample in the polymorphism-discovery panel; E001–E023 are EAs, and
D001–D040 are AAs. Each column corresponds to a polymorphic site.
Sites are ordered by LD, not position along the chromosome, with
sites showing similar patterns of genotype shown adjacent to one an-
other. Site numbers are relative to GenBank accession number
AF449713. Selected tagSNPs are indicated with arrows.
activity. Participants eligible for the current study in-
cluded those who consented to isolation of genomic
DNA from peripheral-blood leukocytes obtained at the
year 10 examination and for which an adequate DNA
sample was available ( ).np 3,790
Phenotypic Measurements and Statistical Analysis
Plasma CRP levels were assayed using BNII immuno-
nephelometry (BNII Nephelometer 100 Analyzer [Dade
Behring]) on plasma, stored at year 7, from 3,382 re-
turning CARDIA participants who also consented to
DNA testing and on plasma from 3,146 consenting par-
ticipants who returned at year 15. The latter number
represents 86% of the 3,672 original CARDIA subjects
who attended the year 15 examination. Two CRP mea-
surements were available at year 15, BNII and ELISA.
BNII is a more sensitive assay than ELISA (Wener et al.
2000), so only the results of analysis of the BNII data
are presented, although results from an analysis of the
ELISA data at year 15 were consistent (data not shown).
BNII plasma CRP measurements had a range of 0–333
mg/liter. Samples with ELISA-based CRP 110 mg/liter
have been suggested to represent acute illness, stress, or
infection (Shine et al. 1981; Pearson et al. 2003); 48 such
samples were observed at year 15, comparable to the 50
samples with BNII CRP 118 mg/liter at year 15. Exclu-
sion of samples with BNII 118 mg/liter had negligible
impact on results at either year 7 or year 15 (data not
shown). Plasma-CRP measurements at years 7 and 15
were significantly correlated for samples above this
threshold, so samples with high CRP measurements were
not removed from the analysis.
Stepwise linear regression was run in the R statistics
program v2.0.1, with ln(plasma CRP) (the natural log
of plasma CRP) at year 7, ln(plasma CRP) at year 15,
or change in ln(plasma CRP) between years 7 and 15
as the dependent variable. The following phenotypic
measures were allowed to enter the model as indepen-
dent variables: ln(BMI), age, sex, ethnicity, systolic blood
pressure, diastolic blood pressure, ln(glucose), ln(insu-
lin), ln(total cholesterol), ln(HDL), ln(LDL), and ln(insu-
lin/glucose). The Bayesian information criterion (Hastie
et al. 2001), a measure of how well each model fits the
data that is penalized for the number of parameters in
the model, was used for all model comparisons.
For each of the dependent variables (CRP at year 7
and CRP at year 15), independent variables retained in
the best-fit model at both time points were included as
covariables in an analysis of the effects of haplotype on
ln(plasma CRP). Analyses were run using the haplo.stats
package for R (Lake et al. 2003), a generalized linear-
regression framework that incorporates haplotype phase
uncertainty by inferring a probability matrix of haplo-
type likelihoods for each individual by use of the expec-
tation-maximization (EM) haplotype-inference algorithm
rather than by assignment of a most likely haplotype
phase resolution to each sample. Haplo.stats analysis
was performed on the complete CARDIA cohort, with
race and sex included as covariables, as well as on sub-
sets of the CARDIA cohort stratified by sex and race.
Haplo.stats analysis was restricted to haplotypes with
an inferred frequency 11%, representing ∼33 chromo-
somes in this cohort.
In Vitro Promoter-Variant Vector Construction
PCR products from the CRP promoter region repre-
senting several haplotypes were cloned into a modified
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Figure 3 Phylogeny of common CRP haplotypes. Haplotypes
were inferred for all 18 common SNPs (MAF 110% in either AA or
EA sequenced samples) by use of PHASE v 2.0. A neighbor-joining
phylogenetic tree of the major CRP haplotypes resolved using the seven
selected tagSNPs is shown, with branch lengths representing evolution-
ary distance as the proportion of alleles shared at all 18 common SNPs.
The tagSNP alleles associated with each resolved haplotype are shown.
Table 3
tagSNP Allele Frequencies in SNP Discovery and CARDIA Populations
SNP
dbSNP
NUMBER ALLELES
ALLELE FREQUENCIES (%) IN
AA EA
Sequenced Samples
( )np 24
CARDIA Cohort
( )np 1,557
Sequenced Samples
( )np 23
CARDIA Cohort
( )np 1,820
790 rs309358 A/T 77/23 83/17 100/0 100/0
1440 rs3091244 A/C/T 33/26/41 26/45/29 5/62/33 7/64/30
1919 rs1417938 A/T 83/17 88/12 70/30 70/30
2667 rs1800947 C/G 2/98 1/99 4/96 6/94
3006 rs3093066 A/C 29/71 23/77 0/100 0/100
3872 rs1205 A/G 15/85 19/81 25/75 34/66
5237 rs2808630 A/G 94/6 82/18 65/35 72/28
pGL3-basic luciferase expression vector (Promega). Short
and extended clones of the native promoter represent bps
540–1726 and bps 1023–1726, respectively, relative to
GenBank AF449713 (corresponding to positions 1186
to 1 and 703 to 1, relative to the transcription
start site (TSS) discussed by Li et al. [1990]). To reduce
interleukin 6 (IL6) dependence, the proximal CRP pro-
moter (107 to 1, relative to TSS) was replaced with
the SV40 minimal promoter (bps 2349–2513 of pDs-
Red2-C1 [Promega]). Construct sequences were verified
by standard fluorescent resequencing, and all construct
sequences have been deposited into GenBank. Maxipreps
of each construct were made (Plasmid Maxi Kit, part
#12162 [QIAGEN]) and were diluted to a concentration
of 200 ng/ml by UV densitometry, verified by ethidium
bromide staining of serial dilutions in agarose gels.
Luciferase Assays
Transient transfection assays were conducted in a hu-
man liver hepatoma cell line (PLC/PRF/5 cells from ATCC
[Manassas]) in 24-well plates, with 24 replicate wells
per construct per experiment. Cells were seeded in se-
rum-containing media. After 24 h, cells were transfected
in serum-free media (so that transfection time also served
as serum-starvation time). In each well, 200 ng of plas-
mid was transfected, with Fugene 6 transfection reagent
(Roche Diagnostics), per protocols provided with the
reagent. After 18 h, transfection media was removed,
and cells either were induced with 200 U/ml human IL6
(Stem Cell Technologies) in serum-free media or were
mock induced with non-IL6–containing serum-free me-
dia. Cell lysates were prepared 24 h later, and luciferase
activity was assayed in a Wallac plate luminometer, per
protocols of the Luciferase Assay System (Promega).
For each 24-well data set, the two highest and the two
lowest values were dropped to remove outliers possibly
related to variation in transfection efficiency. For the
remaining data, luciferase values were normalized to the
average activity of the promoter-less empty vector in na-
tive promoter experiments or to the SV40 minimal pro-
moter alone in replacement promoter experiments, to
yield data reflecting fold-activity increase over baseline
levels for each CRP promoter construct. Standard error
measurements and two-tailed student’s t tests were used
to assess the significance of differences between haplo-
type constructs.
Results
SNP Discovery and Selection of CRP Gene tagSNPs
Polymorphisms in the CRP gene region were identified
by direct resequencing of 47 individuals: 24 AAs and
23 EAs. We identified 31 SNPs overall, 30 polymorphic
in AAs and 13 polymorphic in EAs (fig. 1). No amino
acid–changing SNPs were identified in either population.
There were 18 common SNPs (i.e., SNPs with a relative
MAF 110% in at least one of the two populations). Ten
unique CRP haplotypes were inferred from the 18 com-
mon SNPs by use of a Bayesian statistical method for
haplotype reconstruction (PHASE v2.0) (Stephens et al.
2001).
We next used an LD-based tagSNP-selection algorithm
(LDselect) (Carlson et al. 2004) at a threshold of 2r 1
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Table 4
tagSNP Haplotype Frequencies in SNP Discovery
and CARDIA Populations
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
Table 5
Best-Fit Model Predictors of ln(plasma CRP) Level
at Year 7, in All Subjects ( )Np 3,051
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
, and we identified five tagSNPs that summarize com-0.64
mon patterns of variation across the CRP gene in the
sequenced samples (fig. 2). Two additional SNPs—a
common triallelic SNP from the promoter region and a
rare, synonymous SNP that previously was associated
with CRP level (Zee and Ridker 2002)—were selected
for analysis independent of the LDselect results. The
seven tagSNPs resolved the 10 unique haplotypes ob-
served in the sequenced samples as eight clades of related
haplotypes (fig. 3), with each tagSNP allele tagging either
a specific haplotype (SNPs 790, 1919, 2667, 3006, and
5237) or a clade of evolutionarily related haplotypes
(SNP 1440 and 3872).
CRP Genotype-Phenotype Association Study
We subsequently genotyped the seven selected tagSNPs
in 3,790 U.S. adults recruited as part of the CARDIA
study (Hughes et al. 1987; Friedman et al. 1988). The
subjects, who were aged 18–30 years at baseline, have
been followed prospectively for 15 years and have under-
gone serial assessment for various cardiovascular risk
factors (table 2). Allele frequencies at all tagSNPs were
consistent between the sequenced samples and the CAR-
DIA cohort (table 3), although tagSNP allele frequencies
differed significantly between AAs and EAs. Inferred
haplotype frequencies were also similar between the se-
quenced samples and the CARDIA cohort (table 4).
Stepwise linear regression of log-transformed CRP val-
ues on selected clinical, demographic, and lifestyle mea-
surements identified six statistically significant predictors
at both year 7 and year 15—BMI, race, sex, triglycerides,
insulin level, and current smoking—as well as two sig-
nificant interactions on CRP level, between sex and tri-
glycerides ( ) and between sex and smokingP ! .0001
( ). Best-fit models at each time point are shownP ! .0001
in table 5 (year 7) and table 6 (year 15). At both time
points, the interaction between sex and triglycerides re-
flects a strong association with triglyceride levels in
women and a weak association in men, and the inter-
action between sex and smoking reflects a strong asso-
ciation with smoking in men but not in women (data
not shown).
There was significant variation in CRP level among
CRP haplotypes ( ), and the patterns of associa-6P ! 10
tion were similar at both time points (fig. 4 and tables
7 and 8) as well as in analyses stratified by sex and race
(data not shown). The results of a similar analysis with-
out covariables were also consistent (data not shown).
Haplotype 1 (H1) (tagged by SNP 2667) was associated
with significantly reduced CRP levels relative to H2, the
referent, at both time points. In addition, the clade of
H1–H4, which carry the C allele of the triallelic SNP
1440, was associated with lower CRP levels than was
the clade of H5–H8. Of the latter group, H6 (tagged by
SNP 790) was associated with the highest CRP levels
relative to all other haplotypes. The results of a similar
analysis without covariables were also consistent (data
not shown). Models fitted under the assumption of allelic
independence showed a better fit than did recessive or
dominant models at any of the loci (data not shown).
Models fitted without interactions between haplotype and
phenotypic variables other than race showed a better fit
than did models including such interactions (data not
shown). Exclusion of the 48 subjects with BNII CRP
values 118 mg/liter did not alter these results. Similarly,
exclusion of the upper and lower 5% of CRP values did
not alter the results, so it is unlikely that the observed
associations were attributable to a small number of in-
fluential data points. Comparison of the residual vari-
ance of the full model with the residual variance of mod-
els excluding single predictors demonstrated that only
BMI explained a greater proportion of variance than did
the tagSNPs at both time points (table 9). Results were
similar for analyses stratified by race (data not shown).
The availability of high-sensitivity BNII CRP measure-
ments at time points 8 years apart allowed us to assess
the potential influence of CRP genotype on the temporal
change in CRP level. Overall, the intrasubject correla-
tion in ln(CRP) between years 7 and 15 was rp 0.60
( ). On average, there was a 0.33 mg/liter, orP K .001
11.6%, increase during the 8-year interval. Although
change in BMI and change in triglycerides were signifi-
cantly correlated with change in CRP level, there were
no significant associations between CRP haplotype and
change in level (data not shown).
Contribution of CRP Genotype to Population
Differences in CRP Levels
Median CRP levels were 1.0 mg/liter among EAs and
2.0 mg/liter among AAs ( by t test on log-trans-6P ! 10
formed data). Since the low-level CRP variant (H1) was
more common among EAs and the high-level variant (H6)
was more common among AAs, we assessed the extent
to which CRP genotype or other known predictors ac-
counted for variation in CRP levels between AAs and
EAs in our population sample. To this end, we analyzed
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Table 6
Best-Fit Model Predictors of ln(plasma CRP) Level
at Year 15, in All Subjects ( )Np 2,995
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
a series of nested, multivariable regression models that
variably included or excluded terms for race/ethnicity,
sex, BMI, triglycerides, insulin level, smoking status,
and CRP haplotypes or tagSNP genotypes. The non-
genotypic covariables sex, triglycerides, insulin level, and
smoking status all contributed relatively little to the
mean difference in CRP level between racial groups, es-
timated from the regression model—mean difference in
ln(CRP) unadjusted;levelp 0.55 0.04 0.43 0.04
adjusted for sex, triglycerides, insulin level, and smoking
status. The further addition of BMI to the regression
model had a more substantial effect—mean difference
in ln(CRP) —suggesting that morelevelp 0.20 0.04
than half of the difference in CRP levels between ethnic
groups was attributable to differences in BMI between
AAs and EAs. The addition of CRP genotypes to the
model resulted in an even greater reduction in the co-
efficient for ethnicity (e.g., mean difference in ln(CRP)
at year 15 [table 8]), to the pointlevelp 0.04 0.05
where there was no longer a statistically significant dif-
ference between racial groups at either time point (Pp
[table 7]; [table 8])..51 Pp .41
CRP Promoter Analysis In Silico
Comparison of the human and mouse genomic se-
quence of the CRP locus (Mayor et al. 2000) showed a
strongly conserved promoter region 5′ of the exons (fig.
5, upper panel) that contains response elements for sev-
eral hepatic transcription factor families (HNF, C/EBP,
and NFKB) involved in induction of CRP by IL6 (Li et
al. 1990). Two SNPs map to the 5′ edge of this region,
tagSNP 1440 and a SNP perfectly associated with tagSNP
790, 1421. A transcription factor–motif analysis of the
region (TFSEARCH; Heinemeyer et al. 1998) identified
two upstream stimulating factor 1 (USF1)–binding mo-
tifs altered by SNPs 1421 and 1440 (fig. 5, lower panel).
Only two other USF1-binding motifs were predicted
within the CRP transcript or upstream region, at 1630
and 2650.
In Vitro Gene-Reporter Assays
In light of the observed associations between promot-
er-region polymorphism and CRP levels, as well as the
in silico promoter analysis, in vitro assays were gener-
ated to explore the variation identified in promoter poly-
morphisms in CRP. Each of the five unique promoter-
region haplotypes was cloned into a luciferase-reporter
plasmid for in vitro analysis. Promoter activity in the
native promoter constructs was weak without IL6 in-
duction (fig. 6). Therefore, we also analyzed each pro-
moter haplotype with the native TSS replaced by the
SV40 TSS to generate detectable signal without IL6 in-
duction (fig. 7). The IL6-induced native H7/H8 con-
structs showed elevated promoter activity relative to
H1–H3 (fig. 6) but not in the SV40-replacement con-
structs (fig. 7), suggesting that the elevated CRP levels
associated with H7/H8 require the proximal IL6 re-
sponsive element. By comparison, in the native pro-
moter, there was no evidence of increased IL6-induced
promoter activity from H5 or H6.
Dramatically stronger uninduced expression was ob-
served in the SV40-replacement constructs, and signifi-
cant variation was observed between haplotypes (fig. 7).
Consistent with the CRP genotype-phenotype association
observed in the population study, the H6 promoter
showed the highest activity, and the promoter activity
associated with the H5 construct was also significantly
increased. Interestingly, the magnitude of the difference
between H5/H6 and H1–H4 SV40-replacement pro-
moter activities was similar both with and without IL6
induction, suggesting that, although the H5 and H6 pro-
moter haplotypes associate with elevated CRP levels, this
association is not IL6-dependent but, rather, reflects a
change in basal promoter activity.
Discussion
To determine how common genetic variants at the hu-
man CRP gene locus influence plasma CRP, we used a
three-stage experimental design. In the first phase, all com-
mon genetic variation across the gene region was defined
by resequencing the region in a multiethnic variation
discovery panel, and tagSNPs representative of all com-
mon patterns in each ethnicity were selected for geno-
typing in a larger panel of clinically phenotyped samples.
Seven tagSNPs were selected for genotyping, and these
defined eight common haplotypes (fig. 3). In the second
phase, associations between haplotypes of tagSNPs and
CRP levels were investigated using standard regression
models, and significant associations were identified for
several SNPs in the putative promoter region. In the third
phase, the observed associations were experimentally
validated by in vitro CRP promoter analysis in human
hepatocytes.
The results from our large population sample suggest
that CRP haplotypes can be grouped into four categories
on the basis of associated CRP level: lowest (H1), low
(H2–H4), high (H5, H7, and H8), and highest (H6)
(fig. 4). These results were consistent between year 7
and year 15. Relative to the covariable-adjusted popula-
tion mean of 3.1 mg/liter at year 15, the haplotype as-
sociated with the lowest levels (H1) decreased plasma
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Table 7
Association of CRP Haplotypes with Plasma CRP Level at Year 7
Variable tagSNP Alleles Haplotype Frequencya Coefficient SE t P
Intercept … … 8.0161 .0703 … …
EA … … .0332 .0502 .661 .509
Male … … 1.0083 .1817 5.549 !.00001
ln(BMI) … … 2.4367 .1008 24.18 !.00001
ln(insulin) … … .1963 .0511 3.845 .00012
ln(triglycerides) … … .2996 .0722 4.151 .00003
Current smoker … … .7819 .1406 5.561 !.00001
H1 ACACCAA .0381 .1262 .0728 1.734 .0831
H2 ACAGCAA .2306 Referent … … …
H3 ACAGCGA .0398 .1387 .0725 1.912 .056
H4 ACAGCGG .2215 .0563 .0393 1.432 .152
H5 ATTGCGA .2053 .2818 .0398 7.085 !.00001
H6 TTAGCGA .0717 .4498 .0592 7.602 !.00001
H7 AAAGCGA .0481 .3128 .0669 4.677 !.00001
H8 AAAGAGA .0948 .1749 .054 3.236 .00122
Otherb … .0502 .1908 .0705 2.706 .00685
Sex # ln(triglycerides) … … .367 .0441 8.324 !.00001
Sex # smoking … … .3587 .0877 4.091 .00004
NOTE.—t statistics and P values were calculated from the coefficients and SEs within the best-fit multivariate
model by the haplo.glm function of the haplo.stats R package.
a Haplotype frequencies were inferred using the EM algorithm within the haplo.stats package.
b Haplotypes with frequency !1% were pooled as “Other.”
Table 8
Association of CRP Haplotypes with Plasma CRP Level at Year 15
Variable tagSNP alleles Haplotype Frequencya Coefficient SE t P
Intercept … … 7.1203 .0745 … …
EA … … .0405 .0495 .819 .413
Male … … 1.69 .1824 9.265 !.00001
ln(BMI) … … 2.4717 .0963 25.657 !.00001
ln(insulin) … … .2016 .0438 4.605 !.00001
ln(triglycerides) … … .4544 .0671 6.771 !.00001
Current smoker … … .7411 .1456 5.09 !.00001
H1 ACACCAA .0378 .2275 .0717 3.172 .00153
H2 ACAGCAA .2262 Referent
H3 ACAGCGA .0414 .0335 .0706 .475 .635
H4 ACAGCGG .2231 .0534 .0386 1.381 .167
H5 ATTGCGA .205 .2125 .0391 5.437 !.00001
H6 TTAGCGA .0733 .5219 .0573 9.107 !.00001
H7 AAAGCGA .0475 .3152 .066 4.778 !.00001
H8 AAAGAGA .096 .2044 .0531 3.851 .00012
Otherb … .0496 .1552 .0725 2.142 .0323
Sex # ln(triglycerides) … … .4801 .0418 11.487 !.00001
Sex # smoking … … .3583 .0914 3.918 .00009
NOTE.—t statistics and P values were calculated from the coefficients and SEs within the best-fit multivariate
model by the haplo.glm function of the haplo.stats R package.
a Haplotype frequencies were inferred using the EM algorithm within the haplo.stats package.
b Haplotypes with frequency !1% were pooled as “Other.”
CRP an average of 1.5 mg/liter per copy, whereas the
haplotype associated with the highest levels (H6) in-
creased plasma CRP 1.5 mg/liter per copy.
An advantage of using tag SNPs defined on the basis
of detailed sequence variation and LD data is that map-
ping the observed haplotype associations to potentially
functional polymorphisms (or combinations thereof) can
be straightforward. For example, the synonymous SNP
at 2667 was the only observed difference between H1
and H2 in the SNP discovery samples. Therefore, it is
likely that this polymorphism directly influences CRP
levels, consistent with previous reports (Szalai et al. 2002;
Zee and Ridker 2002; Brull et al. 2003; Russell et al.
2004), although the mechanism for a direct effect is
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Table 9
Proportion of Variance Explained
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
Figure 4 Relative effects of tagSNP haplotypes on ln(CRP). Regression coefficients from haplo.glm analysis were estimated for each
haplotype, with phenotypic variables included as covariables. Coefficients reflect difference in mean ln(CRP) per copy relative to H2, the most
frequent haplotype. H1 was significantly lower than H2, and H5–H8 were significantly higher (see P values in tables 7 and 8).
unclear, so it remains possible that 2667 is in strong LD
with a polymorphism in a distal regulatory element not
within the region scanned for polymorphisms. Similarly,
the sole consistent difference between the clade of hap-
lotypes associated with low CRP levels (H1–H4) and
the clade of haplotypes associated with higher CRP lev-
els (H5–H8) appears to be the genotype at the triallelic
promoter SNP 1440 (fig. 1); the low clade is associated
with the C allele and the high clade with A or T alleles.
Finally, the rare alleles at five SNPs (tagSNP 790 and
unassayed SNPs 1123, 1421, 4741, and 6333) are re-
stricted to the haplotype associated with highest CRP
levels (H6), so the observed effect of this haplotype
could be attributable to a haplotype of several of these
SNPs.
Interestingly, stepwise regression analysis with pheno-
type and tagSNP genotype as independent variables iden-
tified exactly the same set of tagSNPs as being function-
ally important, because the functionally important hap-
lotypes were uniquely associated with the rare allele of
a single tagSNP. A haplotype-based analysis would have
proven advantageous only if one of the haplotypes with-
out such a tagSNP (H2, H3, or H7) showed a significant
effect on CRP. In this case, haplotype analysis could
even be considered a disadvantage because of the effort
required to map the observed haplotype effects to spe-
cific tagSNPs, whereas direct tagSNP analysis immedi-
ately identified the key tagSNPs. Haplotype analysis
may prove more powerful in genes with more complex
recombination histories or when haplotype-tagging SNPs
have not been comprehensively described, but our ex-
ample demonstrates that haplotype-based analysis is not
necessarily superior to direct tagSNP analyses.
To address the possibility that SNPs in the upstream
region are functionally important in regulation of the
CRP gene, haplotypes of the minimal (703 to1, rela-
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Figure 5 CRP promoter and predicted USF1 sites. Upper panel, A vista plot (Mayor et al. 2000) of mouse homology across the human
CRP locus. The CRP transcript and repeat elements are annotated across the top of the plot (see key at left), and strong evolutionary conservation
of the coding region in the second exon is apparent as the shaded blue peak. A putative promoter region (75% conserved) is visible as a pink
peak stretching from 1444 to 1650; the two putatively functionally polymorphic USF1 sites (1421 and 1440) are on the edge of this region.
Lower panel, Haplotypes of the polymorphisms at 1421 and 1440, with the putative USF1-binding sites indicated in uppercase letters. Alleles
predicted to disrupt USF1 binding are shown in red, and alleles predicted to retain USF1 binding are shown in green. H1–H3 represents the
ancestral haplotype, as inferred from the chimpanzee alleles at these SNPs. LINE p long interspersed nuclear element; LTR p long terminal
repeat; SINE p short interspersed nuclear element.
tive to the TSS) and (1186 to1 ) extended promoter
region were cloned into a luciferase-reporter plasmid
for promoter-activity analysis. Some of the tagSNP hap-
lotypes across the CRP region did not differ in the pro-
moter region (e.g., H1–H3), so a single promoter con-
struct represented these haplotypes. The relative basal
and IL6-induced expression from each of the five unique
promoter haplotypes was assessed in cultured human
hepatoma cells. Basal expression levels for the native CRP
promoter revealed no clear trend, because basal expres-
sion was quite weak (fig. 6). However, IL6-induced pro-
moter activity from the H7/H8 constructs (tagged by
the 1440 A allele) was marginally higher than all other
haplotype constructs ( [uncorrected for multipleP ! .05
tests]). These results are consistent with the higher CRP
levels associated with H7/H8 observed in the human
population data. IL6-induced activity is a better model
for CRP levels during an acute phase response than are
basal CRP levels. Nonetheless, over time, we did not
observe any apparent influence of H7/H8 on change in
CRP levels.
The weak constitutive activity of the CRP promoter
appears to be due to a negative regulatory element lo-
cated within the proximal promoter region (Li et al.
1990). Therefore, we performed additional experiments
in which we replaced the 107 bp adjacent to the TSS
(including the proximal IL6-responsive elements present
within the CRP promoter region) with the SV40 minimal
promoter. As expected, the SV40-replacement promoter
construct showed dramatically higher activity (fig. 7). For
some haplotype comparisons, it was possible to assign
the functional difference to a single SNP, because the
constructs differed at only one SNP. For example, the
significant difference observed between the H5 and H1–
H3 constructs (fig. 7) is entirely attributable to the allele
at SNP 1440 (C vs. T), which was the only sequence
difference between these constructs. Similarly, the sig-
nificant difference between the H4 and H1–H3 con-
structs is entirely attributable to SNP 1009. Thus, the
marginally significant trend toward higher CRP levels
that we observed for H4 in our population sample (fig.
3) may truly represent a functional effect of the H4-
associated SNP 1009, as suggested elsewhere (Wolford
et al. 2003). The significant difference observed between
the H6 and H5 constructs might be attributable to any
one of several polymorphic sites, but data from the
shorter SV40-replacement constructs suggest that this
difference is attributable to either 1123 or 1421 (fig. 7).
Of particular interest are the short replacement pro-
moter constructs that reveal significantly different tran-
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Figure 6 Native promoter construct activity. Short (703 to 1, relative to TSS) and extended (1186 to 1) versions of the CRP
promoter region were cloned into a luciferase-reporter–gene plasmid. Transient transfection data show the increase in transcription levels for
each construct over that of the plasmid-lacking promoter in both uninduced and IL6-induced environments. Shaded circles identify minor alleles
at a given SNP. Unshaded circles identify one of the triallelic SNP variants at bp 1440. Error bars reflect SEM in 20 replicate experiments. The
short construct group of H1–H4 is divided into two categories of long clones on the basis of the unique 1009 SNP in H4 that is not included
in the short-clone constructs. Within the IL6-induced extended constructs, t tests show that H4 activity is significantly reduced, whereas H7–
H8 activity is significantly increased ( ), consistent with the induced short constructs in which t tests show that H1–H4 activity is significantlyP ! .05
reduced, whereas H7–H8 activity is significantly increased ( ). Uninduced activities showed similar trends, but the signal was relativelyP ! .05
weak.
scriptional activity that is based solely on the allele at
triallelic SNP position 1440. Previous reports of in-
creased CRP levels associated with SNP 3014, which is
restricted to H5 in Europeans (Brull et al. 2003; Russell
et al. 2004), might reflect LD with the functional 1440T
allele, although the 3014 polymorphism could conceiv-
ably be functional in addition to the demonstrated func-
tional changes at 1440, because it is in the 3′ UTR and
might affect RNA structure or turnover.
In contrast to the H5 and H6 results, in which the
in vitro assays lend strong support to the hypothesis
that the observed association between these haplotypes
is largely attributable to functional polymorphisms with-
in the promoter region, the in vitro results for H7 and
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Figure 7 SV40-replacement promoter construct activity. To increase the level of uninduced expression, an IL6-responsive negative regulatory
element in the proximal segment of the CRP promoter (107 to 1) was replaced with the SV40 minimal promoter. Transient transfection
data shows the increase in transcription levels for each construct over that of the SV40 minimal promoter alone. Shaded circles identify minor
alleles at a given SNP. Unshaded circles identify one of the triallelic SNP variants at bp 1440. Error bars reflect SE measurements. Within each
combination of construct length and induction condition, t tests show that all differences between haplotypes’ behavior are significant (P !
), except for H1–H3 versus H7–H8 in IL6-induced extended constructs..05
H8 provide, at best, weak support for the observed as-
sociations. This might reflect one of several possibilities:
the 1440A allele may indeed be functionally different
from the 1440C allele but not under the conditions as-
sayed. That is, in addition to IL6, IL1B and tumor ne-
crosis factor a are known to regulate CRP, and H7 and
H8 may behave differentially in response to these or
other as-yet-unidentified signals but not in the basal
activity assay or under IL6 induction. Alternatively, the
association for these haplotypes may be the result of a
polymorphism that is in strong LD with the 1440 A
allele but falls outside of the region assayed for pro-
moter activity. Curiously, there were only four SNP al-
leles restricted to H7 and H8: 969C, 1440A, 6192A,
and 6469G. The first two were within the analyzed
promoter region for the long clones, whereas the latter
two SNPs are 12,000 bp past the polyadenylation site
of the transcript and do not appear to lie in regions of
strong evolutionary conservation that would suggest a
distal regulatory element. Thus, at this time, we have
not identified a good candidate SNP outside of the pro-
moter region to account for the elevated activities of H7
and H8.
These experimental results support the hypothesis that
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the CRP haplotype-phenotype associations observed in
the CARDIA cohort are at least partially attributable
to functional changes at promoter sites 1421 and 1440,
each of which is also predicted to alter binding motifs
for the transcription factor USF1. The clustering of USF1
sites in the promoter region (fig. 5) suggests that USF1
may play an important role in regulation of the CRP
gene. The increased promoter activities associated with
H5–H8 are particularly interesting in light of recent
publications highlighting the potential importance of
USF1 as a regulator of glucose and lipid-metabolism
genes (Pajukanta et al. 2004).
African-descent populations have higher average CRP
levels than do European-descent populations (Wener et
al. 2000), although there is broad overlap in the range
of levels across ethnic groups. Self-reported ethnicity in
the United States is also associated with differences in
morbidity and mortality from CVD and metabolic dis-
eases, for a variety of medical, social, behavioral, and
economic reasons (Watkins 2004). Thus, the genetic
portion of the interethnic variance appeared to be at-
tributable to frequency differences at three CRP SNPs
(790, 1440, and 2667), in which the allele associated
with lower CRP levels (790A, 1440C, and 2667C) was
more frequent in EAs than in AAs. These results confirm
recent observations that metabolic factors such as obe-
sity account for a large portion of the variation in CRP
levels associated with race/ethnicity (Albert et al. 2004;
Anand et al. 2004) and suggest that the majority of the
remaining variation in CRP levels associated with race/
ethnicity in young adults is accounted for by genetic vari-
ants within the CRP locus.
It remains unclear whether CRP is a risk marker for
inflammatory processes or is causally involved in the
pathogenesis of CVD. The strong associations between
CRP genotype and plasma-CRP level described here do
not resolve this question directly but may prove useful
in testing the hypothesis that CRP levels play a causal
role in CVD pathogenesis. The functional CRP promot-
er variants appear to alter CRP levels independent of
other CRP correlates, particularly BMI, and do so con-
sistently within individuals over time. Thus, we expect
that if CRP is causally involved in disease pathogenesis,
then alleles associated with high CRP levels should be
associated with greater risk of CVD. Currently, the av-
erage age in the CARDIA cohort is 42 years, so the
number of incident CVD events is as yet insufficient to
test this hypothesis. However, large, multiethnic human
studies of older adults that assess atherosclerotic disease
progression or occurrence of clinical cardiovascular
events (such as myocardial infarction) can be used to
address this important question. Such studies are cur-
rently in progress. Commonly prescribed cholesterol-
lowering drugs, such as statins and PPARa activators,
may additionally reduce cardiovascular risk through
anti-inflammatory effects, including attenuation of con-
stitutive and induced CRP gene expression (Kleemann
et al. 2004; Ridker et al. 2005). Therefore, further char-
acterization of the influence and interaction of common
cis-acting nucleotide substitutions on transcriptional
regulation of the CRP gene could have broad implica-
tions for the treatment and prevention of cardiovascular,
metabolic, and related inflammatory disorders.
Note added in proof.—Functional associations be-
tween the 1440 and 1421 promoter SNPs and basal
CRP levels have been confirmed in an independent study
by Szalai et al. (in press).
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